Dynavax Technologies Corp (NAS:DVAX)
$ 13 -0.03 (-0.23%) Market Cap: 1.71 Bil Enterprise Value: 1.17 Bil PE Ratio: 100.23 PB Ratio: 2.51 GF Score: 70/100

Dynavax Technologies Corp at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) Transcript

Oct 25, 2023 / 05:00PM GMT
Release Date Price: $13.94 (-2.45%)
Ed White
H. C. Wainwright & Co., LLC - Analyst

Hello, everyone, and thank you for joining the H. C. Wainwright Fourth Annual Hepatitis B Virus Virtual Conference. My name is Ed White, and I'm a senior analyst here at H. C. Wainwright covering Dynavax Technologies, ticker DVAX.

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing novel vaccines utilizing innovative adjuvant technology. HEPLISAV-B is the company's two-dose vaccine that is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 and older.

Now it is my pleasure to introduce Kelly MacDonald, CFO of Dynavax. Thanks for taking part in the conference, Kelly.

Kelly MacDonald
Dynavax Technologies Corporation - CFO & SVP

Thank you, Ed, and thank you all for joining us today. Before we begin, I'd like to recognize that the presentation contains forward-looking statements that have certain risks and uncertainties that are highlighted in our Risk Factors, in the Form 10-Q, as well as our other SEC

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot